Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 5/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.42 |
| ▸ | FES | P07332 | 2/20 | 0.42 |
| ▸ | HCK | P08631 | 2/20 | 0.42 |
| ▸ | FER | P16591 | 2/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374483 | 0.89 | CDK5 (0.46) | CYP1A2CYP2D6ALDH1A1HSD17B10LMNA | |
| SCHEMBL374779 | 0.76 | FGFR3 (0.55) | CYP1A2CYP3A4RETKDRJAK2 | |
| SCHEMBL374274 | 0.74 | TNNI3K (0.53) | CYP1A2CYP2D6ALDH1A1HSD17B10LMNA | |
| SCHEMBL27700561 | 0.72 | CDK5 (0.45) | CYP1A2CYP2D6ALDH1A1HSD17B10LMNA | |
| SCHEMBL374501 | 0.71 | FGFR3 (0.72) | CYP1A2CYP3A4RETKDRJAK2 | |
| SCHEMBL374155 | 0.70 | ABL1 (0.62) | CYP1A2CYP3A4TNNI3KABL1EGFR | |
| SCHEMBL374332 | 0.70 | THRB (0.74) | TNNI3KRAF1MAPK14KDRAURKA | |
| SCHEMBL373960 | 0.69 | EGFR (0.57) | CYP1A2CYP2D6ALDH1A1HSD17B10LMNA | |
| SCHEMBL28031727 | 0.68 | EPHX2 (0.49) | CYP3A4MKNK2RETMKNK1CDK8 | |
| SCHEMBL29638488 | 0.68 | SYK (0.39) | CDK8SYKCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | CYP1A2 2591/4885CYP2D6 2846/4885ALDH1A1 4285/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | CYP1A2 2591/4885CYP2D6 2846/4885ALDH1A1 4285/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | CYP1A2 2591/4885CYP2D6 2846/4885ALDH1A1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.